Intended for European healthcare professionals only
Intended for European healthcare professionals only

Genomic alterations in intrahepatic cholangiocarcinoma (iCCA)

Genomic alterations with potential
therapeutic implications have been
identified in ~50% of intrahepatic
cholangiocarcinoma (iCCA) patients,
enabling a more individualised picture
of each patient’s disease biology1

  • Two of the most common genomic alterations
    associated with iCCA include isocitrate
    dehydrogenase (IDH) mutations and fibroblast
    growth factor receptor 2
    (FGFR2) fusions1,2

Potentially targetable genomic
alterations are abundant in iCCA*

*Percentages reported for individual alterations are from different primary analyses and are not all drawn from a single population of patients with iCCA. Although FGFR2 fusions and IDH mutations tend to be mutually exclusive in iCCA, mutations in the “other alterations” category can be found in tumours that also carry other potentially targetable mutations or genetic alterations.2

BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; FGFR2, fibroblast growth factor receptor 2; iCCA, intrahepatic cholangiocarcinoma; IDH, isocitrate dehydrogenase; KRAS, Kirsten rat sarcoma viral oncogene homolog; MSI-H, microsatellite instability-high; NTRK, neurotrophic tyrosine receptor kinase.

Figure based on data from Lowery MA, et al. 2018,1 Ross JS, et al. 2014,2 Farshidfar F, et al. 2017,3 Graham RP, et al. 2014,4 Jain A, et al. 2018,5 and Churi CR, et al. 2014.6

REFERENCES: 1. Lowery MA, et al. Clin Cancer Res. 2018;24:4154–61. 2. Ross JS, et al. Oncologist. 2014;19:235–42. 3. Farshidfar F, et al. Cell Rep. 2017:18:2780–94. 4. Graham RP, et al. Hum Pathol. 2014;45:1630–8. 5. Jain A, et al. JCO Precis Oncol. 2018;2:1–12. 6. Churi CR, et al. PLoS ONE. 2014;9:e115383. 7. Babina IS, Turner NC. Nat Rev Cancer. 2017;17:318–32. 8. Moeini A, et al. Clin Cancer Res. 2015;22:291–300. 9. Touat M, et al. Clin Cancer Res. 2015;21:2684–94. 10. Rizvi S, et al. J Gastrointest Oncol. 2016;7:789–96. 11. Mondesir J, et al. J Blood Med. 2016;7:171–80. 12. Valle JW, et al. Cancer Discov. 2017;7:943–62. 13. Pellino A, et al. Transl Gastroenterol Hepatol. 2018;3:40. 14. Momoi H, et al. J Hepatol. 2001;35:235–44. 15. Winkelmann R, et al. Int J Mol Sci. 2018;19:1421. 16. Solomon JP, et al. Mod Pathol. 2020;33:38–46. 17. Kheder ES, et al. Clin Cancer Res. 2018;24:5807–14. 18. Rizvi S, et al. Semin Liver Dis. 2014;34:456–64. 19. Pandith AA, et al. Urol Oncol. 2013;31:398–406. 20. Gallo LH, et al. Cytokine Growth Factor Rev. 2015;26:425–49. 21. Shibata T, et al. Cancer Sci. 2018;109:1282–91.